{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:15:15Z","timestamp":1793085315650,"version":"4.5.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institute of Optometry"},{"name":"Institute of Optometry"},{"name":"Institute of Optometry"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the efficacy of a myopia control spectacle lens (DIMS) at slowing the progression of myopia in a population of European children in comparison with 0.01% atropine and combined DIMS and atropine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study was a non-randomised experimenter-masked prospective controlled observational study of individuals aged 6\u201318 years with progressing myopia but no ocular pathology. Participants were allocated, according to patient\/parent choice, to receive 0.01% atropine eyedrops, DIMS (Hoya\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MiyoSmart\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) spectacles, combined atropine+DIMS or single vision spectacle lenses (control group). The key outcome variables, cycloplegic autorefraction spherical equivalent refraction (SER) and axial length (AL), were measured at baseline and after three, six, and 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 146 participants (mean age 10.3y \u00b13.2), 53 received atropine, 30 DIMS spectacles, 31 atropine+DIMS, and 32 single vision control spectacles. Generalized linear mixed model analysis revealed for SER, whilst controlling for age and SER at baseline, at each stage all treatment groups had significantly reduced progression compared with the control group (p&lt;0.016). For AL, whilst controlling for baseline age and AL, at 6 and 12 months all treatment groups had significantly less progression than the control group (p&lt;0.005). For SER only, in pairwise comparisons at 12 months the atropine+DIMS group had significantly reduced progression compared with the DIMS only and Atropine only groups (p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a European population, DIMS and atropine are effective at reducing myopia progression and axial elongation in progressing myopia and are most successful at reducing myopia progression when used in combination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0281816","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:41:46Z","timestamp":1676554906000},"page":"e0281816","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":107,"title":["A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine"],"prefix":"10.1371","volume":"18","author":[{"given":"Paolo","family":"Nucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schiavetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhee","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Francis","family":"Edgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2824-4595","authenticated-orcid":true,"given":"Bruce John William","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"4","key":"pone.0281816.ref001","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10654-015-0010-0","article-title":"Prevalence of refractive error in Europe: the European Eye Epidemiology (E(3)) Consortium","volume":"30","author":"KM Williams","year":"2015","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"pone.0281816.ref002","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050","volume":"123","author":"BA Holden","year":"2016","journal-title":"Ophthalmology"},{"issue":"12","key":"pone.0281816.ref003","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10654-013-9856-1","article-title":"Education influences the role of genetics in myopia","volume":"28","author":"VJ Verhoeven","year":"2013","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"pone.0281816.ref004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41588-020-0599-0","article-title":"Meta-analysis of 542,934 subjects of European ancestry identifies new genes and mechanisms predisposing to refractive error and myopia","volume":"52","author":"PG Hysi","year":"2020","journal-title":"Nat Genet"},{"issue":"5","key":"pone.0281816.ref005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications","volume":"25","author":"SM Saw","year":"2005","journal-title":"Ophthalmic Physiol Opt"},{"issue":"4","key":"pone.0281816.ref006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The Complications of Myopia: A Review and Meta-Analysis","volume":"61","author":"AEG Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0281816.ref007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications","volume":"25","author":"SM Saw","year":"2005","journal-title":"Ophthalmic and Physiological Optics"},{"issue":"10","key":"pone.0281816.ref008","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2471\/BLT.12.104034","article-title":"Global cost of correcting vision impairment from uncorrected refractive error","volume":"90","author":"TR Fricke","year":"2012","journal-title":"Bull World Health Organ"},{"issue":"4","key":"pone.0281816.ref009","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6040092","article-title":"Prevention of Progression in Myopia: A Systematic Review","volume":"6","author":"A Vagge","year":"2018","journal-title":"Diseases"},{"issue":"8","key":"pone.0281816.ref010","doi-asserted-by":"crossref","first-page":"e1136","DOI":"10.1111\/aos.14166","article-title":"Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients","volume":"97","author":"M Sacchi","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"pone.0281816.ref011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12886-019-1112-3","article-title":"Efficacy and safety of interventions to control myopia progression in children: an overview of systematic reviews and meta-analyses","volume":"19","author":"E Prousali","year":"2019","journal-title":"BMC Ophthalmology"},{"issue":"3","key":"pone.0281816.ref012","doi-asserted-by":"crossref","first-page":"M106","DOI":"10.1167\/iovs.18-25958","article-title":"IMI\u2014Interventions Myopia Institute: Interventions for Controlling Myopia Onset and Progression Report","volume":"60","author":"CF Wildsoet","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"pone.0281816.ref013","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12886-020-01746-w","article-title":"Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis","volume":"20","author":"C Zhao","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"pone.0281816.ref014","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","article-title":"Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial","volume":"104","author":"CSY Lam","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"pone.0281816.ref015","article-title":"Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study","author":"CS Lam","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"pone.0281816.ref016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.9.9.11","article-title":"Effect of Defocus Incorporated Multiple Segments Spectacle Lens Wear on Visual Function in Myopic Chinese Children","volume":"9","author":"CSY Lam","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"pone.0281816.ref017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/opo.12725","article-title":"Optical and imaging properties of a novel multi-segment spectacle lens designed to slow myopia progression","volume":"40","author":"M Jaskulski","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"key":"pone.0281816.ref018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ajo.2019.12.002","article-title":"The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children","volume":"211","author":"Y Lu","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0281816.ref019","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/eye.2013.256","article-title":"Myopia, an underrated global challenge to vision: where the current data takes us on myopia control","volume":"28","author":"B Holden","year":"2014","journal-title":"Eye"},{"issue":"2","key":"pone.0281816.ref020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"A Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"pone.0281816.ref021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuities charts for clinical research","volume":"94","author":"FL Ferris","year":"1982","journal-title":"American Journal Ophthalmology"},{"key":"pone.0281816.ref022","first-page":"100923","article-title":"Efficacy in myopia control","author":"NA Brennan","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"pone.0281816.ref023","article-title":"One-year myopia control efficacy of spectacle lenses with aspherical lenslets","author":"J Bao","year":"2021","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"pone.0281816.ref024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control","volume":"126","author":"JC Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"pone.0281816.ref025","article-title":"Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration Atropine for Myopia Progression (LAMP) Study","author":"FF Li","year":"2021","journal-title":"Ophthalmology"},{"issue":"6","key":"pone.0281816.ref026","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study","volume":"41","author":"L Joachimsen","year":"2021","journal-title":"Int Ophthalmol"},{"issue":"9656","key":"pone.0281816.ref027","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(08)61930-3","article-title":"De testimonio: on the evidence for decisions about the use of therapeutic interventions","volume":"372","author":"M. Rawlins","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"pone.0281816.ref028","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071444","article-title":"The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children","volume":"10","author":"W Myles","year":"2021","journal-title":"J Clin Med"},{"key":"pone.0281816.ref029","article-title":"Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%","author":"A Chia","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"pone.0281816.ref030","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"JR Polling","year":"2020","journal-title":"Eye (Lond)"},{"key":"pone.0281816.ref031","article-title":"Rebound Effect in the Misight Assessment Study Spain (Mass)","author":"A Ruiz-Pomeda","year":"2021","journal-title":"Curr Eye Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:42:18Z","timestamp":1676554938000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281816"}},"subtitle":[],"editor":[{"given":"James Fielding","family":"Hejtmancik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0281816","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}